“More than half of New York City firefighters say they will not take Pfizer’s COVID-19 vaccine when it becomes available to them in the coming weeks.” [Source: dailymail.co.uk]
Pfizer’s vaccine uses ‘messenger ribonucleic acid’ (mRNA), a molecule containing genetic code that instructs the body to make proteins. By introducing a specific mRNA sequence into the body via a vaccine, the idea is that it will instruct a person’s cells to produce the necessary antigens and generate an immune response against the coronavirus.
While Pfizer claims its vaccine is more than 90 percent effective in preventing COVID-19, the fact is that there is no medium- or long-term data to prove its safety. Nor has Pfizer as yet published the full data from the vaccine’s recent clinical trial.
Traditional vaccines generally take around 10 years to develop, including safety testing and regulatory approval. In contrast, Pfizer’s mRNA vaccine took just 10 months to develop. Despite Pfizer’s claim in its press release that “no serious safety concerns have been observed” (emphasis added), many people will doubtless still have reservations about submitting themselves to receive it. To say that no serious safety concerns have been observed is not the same as saying there are no safety concerns. With the medium- and long-term effects of gene-based vaccines currently being completely unknown, Pfizer’s wording was clearly chosen very carefully.
None of the above should be taken as suggesting that our organization completely opposes all forms of vaccines. We recognize that peptide-based vaccines have potential in the prevention and control of diseases such as cancer, for example. Consisting of short chains of between 2 and 50 natural amino acids, peptides offer a safe and promising new means of fighting disease. Scientists at the Dr. Rath Research Institute in California have already published pioneering work in this area.
To learn more about the dangers of fighting the coronavirus pandemic with ‘genetic vaccines’, visit the Dr. Rath Education website.